Phase II trial of elotuzumab with pomalidomide and dexamethasone for daratumumab-refractory multiple myeloma

被引：2
|
作者：
Parrondo, Ricardo D. [1 ]
Laplant, Betsy R. [2 ]
Elliott, Jamie [1 ]
Fernandez, Andre [1 ]
Flott, Caitlin J. [1 ]
Arrington, Diedre [1 ]
Chapin, Dustin [1 ]
Brown, Jade [1 ]
Das, Saurav [1 ]
Roy, Vivek [1 ]
Chanan-Khan, Asher A. [1 ,3 ]
Ailawadhi, Sikander [1 ,3 ]
机构：
[1] Mayo Clin, Canc Ctr, Dept Hematol Oncol, Jacksonville, FL 32224 USA
[2] Mayo Clin, Quantitat Hlth Sci, Rochester, MN USA
[3] Mayo Clin, Ctr Canc, Dept Canc Biol, Jacksonville, FL 32224 USA
来源：
BLOOD CANCER JOURNAL | 2024年 / 14卷 / 01期
关键词：
D O I：
10.1038/s41408-024-01134-3
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：5
相关论文
共 50 条
  • [1] Phase II Trial of Elotuzumab with Pomalidomide and Dexamethasone for Relapsed/Refractory Multiple Myeloma (RRMM) in the Post-Daratumumab Progression Setting
    Ailawadhi, Sikander
    Parrondo, Ricardo D.
    Laplant, Betsy
    Alegria, Victoria R.
    Elliott, Jamie B.
    Sher, Taimur
    Paulus, Aneel
    Chapin, Dustin
    Heslop, Keisha
    Chanan-Khan, Asher
    Roy, Vivek
    BLOOD, 2022, 140 : 4450 - 4451
  • [2] Outcomes and prognostic indicators in daratumumab-refractory multiple myeloma: a multicenter real-world study of elotuzumab, pomalidomide, and dexamethasone in 247 patients
    Martino, E. A.
    Palmieri, S.
    Galli, M.
    Derudas, D.
    Mina, R.
    Della Pepa, R.
    Zambello, R.
    Vigna, E.
    Bruzzese, A.
    Mangiacavalli, S.
    Zamagni, E.
    Califano, C.
    Musso, M.
    Conticello, C.
    Cerchione, C.
    Mele, G.
    Di Renzo, N.
    Offidani, M.
    Tarantini, G.
    Casaluci, G. M.
    Rago, A.
    Ria, R.
    Uccello, G.
    Barila, G.
    Palumbo, G.
    Pettine, L.
    De Magistris, C.
    Vincelli, I. D.
    Brunori, M.
    Accardi, F.
    Amico, V.
    Amendola, A.
    Fontana, R.
    Bongarzoni, V.
    Rossini, B.
    Cotzia, E.
    Gozzetti, A.
    Rizzi, R.
    Sgherza, N.
    Curci, P.
    Mancuso, K.
    Reddiconto, G.
    Maroccia, A.
    Franceschini, L.
    Bertuglia, G.
    Nappi, D.
    Barbieri, E.
    Quaresima, M.
    Petrucci, M. T.
    Di Raimondo, F.
    ESMO OPEN, 2025, 10 (02)
  • [3] Daratumumab, pomalidomide and dexamethasone combination therapy in daratumumab and/or pomalidomide refractory multiple myeloma
    Hussain, M. Junaid
    Robinson, Myra M.
    Hamadeh, Issam
    Arnall, Justin
    Bhutani, Manisha
    Atrash, Shebli
    Friend, Reed
    Pineda-Roman, Mauricio
    Symanowski, James T.
    Usmani, Saad Z.
    Voorhees, Peter M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 186 (01) : 140 - 144
  • [4] A Phase II Study of Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma
    Yee, Andrew J.
    Laubach, Jacob P.
    Campagnaro, Erica L.
    Lipe, Brea C.
    Nadeem, Omar
    Friedman, Robb S.
    Cole, Craig E.
    O'Donnell, Elizabeth K.
    Bianchi, Giada
    Branagan, Andrew R.
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra A.
    Mann, Mason L.
    Lohr, Jens G.
    Anderson, Kenneth C.
    Richardson, Paul G.
    Raje, Noopur S.
    BLOOD, 2019, 134
  • [5] phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma
    Yee, Andrew
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Sperling, Adam
    Bianchi, Giada
    Munshi, Nikhil
    O'Donnell, Elizabeth
    Branagan, Andrew
    Avigan, David
    Liegel, Jessica
    Harrington, Cynthia
    Agyemang, Emerentia
    Lively, Kathleen
    Packer, Lisette
    Han, Samuel
    Minsky, Cole
    Riadi, Manal
    Mcvey, Cailin
    Donnelly, Kaleigh
    Smith, Caitlin
    Katzeff, Mackenna
    Goguen, Amy
    Horick, Nora
    Richardson, Paul
    Raje, Noopur
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S220 - S221
  • [6] A phase II study of elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew Jenho
    Laubach, Jacob
    Campagnaro, Erica Leigh
    Lipe, Brea
    Nadeem, Omar
    Cole, Craig
    O'Donnell, Elizabeth
    Schlossman, Robert L.
    Bianchi, Giada
    Branagan, Andrew Robert
    Shapiro, Samantha J.
    Harrington, Cynthia C.
    Burke, Jill N.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Thorburn, Cassandra Ann
    Mann, Mason L.
    Lohr, Jens Guenter
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma
    Chari, Ajai
    Suvannasankha, Attaya
    Fay, Joseph W.
    Arnulf, Bertrand
    Kaufman, Jonathan L.
    Ifthikharuddin, Jainulabdeen J.
    Weiss, Brendan M.
    Krishnan, Amrita
    Lentzsch, Suzanne
    Comenzo, Raymond
    Wang, Jianping
    Nottage, Kerri
    Chiu, Christopher
    Khokhar, Nushmia Z.
    Ahmadi, Tahamtan
    Lonial, Sagar
    BLOOD, 2017, 130 (08) : 974 - 981
  • [8] A phase II study of daratumumab with weekly carfilzomib, pomalidomide, and dexamethasone in relapsed and refractory multiple myeloma.
    Yee, Andrew J.
    Nadeem, Omar
    Rosenblatt, Jacalyn
    Bianchi, Giada
    O'Donnell, Elizabeth
    Branagan, Andrew R.
    Harrington, Cynthia C.
    Agyemang, Emerentia A.
    Gammon, Marilyn T.
    Lively, Kathleen J.
    Packer, Lisette A.
    Bernstein, Zachary S.
    Lyons, Rebecca T.
    Riadi, Manal
    Rowell, Sean M.
    Mcvey, Cailin
    Goguen, Amy C.
    Horick, Nora K.
    Richardson, Paul G.
    Raje, Noopur S.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [9] AN INDIRECT COMPARISON OF ELOTUZUMAB, CARFILZOMIB, AND DARATUMUMAB WHEN GIVEN IN COMBINATION WITH POMALIDOMIDE AND DEXAMETHASONE FOR RELAPSED/REFRACTORY MULTIPLE MYELOMA
    Potluri, R.
    Chen, C.
    Ranjan, S.
    Kumar, A.
    Bhandari, H.
    Davis, C.
    VALUE IN HEALTH, 2019, 22 : S104 - S104
  • [10] Phase II Study of the Combination of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Early Relapsed/ Refractory Multiple Myeloma
    Kumar, Anupama
    Rosenberg, Aaron S.
    Padilla, Michelle
    Shah, Nina
    Sirianni, Lindsey
    Liu, Lin
    Cheng, Yuwei
    Pittman, Emily
    Tzachanis, Dimitrios
    Larson, Sarah
    Mulroney, Carolyn
    Ball, Edward D.
    Costello, Caitlin
    BLOOD, 2022, 140 : 4436 - 4437
12345